CNS Drugs provides researchers and healthcare professionals with essential information on the most important aspects of drug therapies used for the management of neurological and psychiatric disorders.

Via a program of reviews and original research articles, the journal addresses major issues relating to drug therapy of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of neurological and psychiatric disorders; and the practical management of specific clinical situations.

As a hybrid journal, CNS Drugs does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require. This is achieved via the Springer Open Choice™ initiative. More information about this optional route to open access and the associated article processing charge can be found by clicking on the ‘Learn about publishing Open Access with us’ link below.

CNS Drugs offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

Journal information

Editors
  • Kate Palmer,
  • Susan Pochon
Publishing model
Hybrid. Learn about publishing Open Access with us

Journal metrics

5.749 (2020)
Impact factor
5.874 (2020)
Five year impact factor
30 days
Submission to first decision
103 days
Submission to acceptance
339,810 (2020)
Downloads

Latest articles

Journal updates

  • Digital Features

    CNS Drugs is able to host a range of digital features, with a number of options available to authors.

    Digital Features
View all updates

About this journal

Electronic ISSN
1179-1934
Print ISSN
1172-7047
Abstracted and indexed in
  1. ANVUR
  2. BFI List
  3. BIOSIS
  4. CNKI
  5. Chemical Abstracts Service (CAS)
  6. Current Contents/ Life Sciences
  7. Current Contents/Clinical Medicine
  8. Dimensions
  9. EBSCO Academic Search
  10. EBSCO Advanced Placement Source
  11. EBSCO Biomedical Reference Collection
  12. EBSCO CINAHL
  13. EBSCO Discovery Service
  14. EBSCO Psychology & Behavioral Sciences Collection
  15. EBSCO Rehabilitation & Sports Medicine Source
  16. EBSCO SPORTDiscus
  17. EBSCO STM Source
  18. EMBASE
  19. Google Scholar
  20. Japanese Science and Technology Agency (JST)
  21. Journal Citation Reports/Science Edition
  22. Medline
  23. Naver
  24. OCLC WorldCat Discovery Service
  25. Pathway Studio
  26. ProQuest Biological Science Database
  27. ProQuest Calcium and Calcified Tissue Abstracts
  28. ProQuest Central
  29. ProQuest Health & Medical Collection
  30. ProQuest Health Research Premium Collection
  31. ProQuest Medical Database
  32. ProQuest Natural Science Collection
  33. ProQuest Neurosciences Abstracts
  34. ProQuest Psychology Database
  35. ProQuest SciTech Premium Collection
  36. ProQuest-ExLibris Primo
  37. ProQuest-ExLibris Summon
  38. PsycINFO
  39. Reaxys
  40. SCImago
  41. SCOPUS
  42. Science Citation Index
  43. Science Citation Index Expanded (SciSearch)
  44. Semantic Scholar
  45. TD Net Discovery Service
  46. UGC-CARE List (India)
Copyright information

Rights and permissions

Springer policies

© Springer Nature Switzerland AG